Cabaletta Bio Inc (CABA) Stock Price, Quote & News

Company Profile

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, non-renal systemic lupus erythe...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 759 3100

Website: www.cabalettabio.com

Address:

2929 Arch Street, Suite 600, Philadelphia, United States

Moonman321 Feb. 4 at 1:34 AM

$CABA $NVDA what a comeback across small caps today. Stimulus tailwinds + incoming rate cuts are lighting the fuse, and CABA sits right in the sweet spot — a potentially life-changing autoimmune reset platform with real institutional interest. When risk comes back on, names like this move fast. Rotation, baby, still in effect for months Thank Covid for this price !! 🚀

0 · Reply

Bronco6970 Feb. 3 at 9:42 PM

$CABA I have a large watch list, 60% are way down. Don’t know what your beef is, but I’ll glad I’m in the 40%. Most of the people on this board are not idiots, the ones accusing usually are the idiots 🤡👇

1 · Reply

nutkicker Feb. 3 at 9:04 PM

$CABA my God you idiots my entire portfolio surged at the end of the day. It's not just CABA. There isn't any magic genie event, something scooped up the entire market dip

1 · Reply

Moonman321 Feb. 3 at 8:33 PM

$CABA you’re obsessed with me 😆

0 · Reply

Moonman321 Feb. 3 at 8:30 PM

$CABA $FVRR $NVDA $PLUG $SKIN Risk on just like that in small caps 💥 This will be a beautiful year for those in small caps

0 · Reply

gata2016 Feb. 3 at 8:25 PM

$CABA Always good to be green on a red day.

0 · Reply

gata2016 Feb. 3 at 8:20 PM

$CABA Back up we go

0 · Reply

Bronco6970 Feb. 3 at 8:19 PM

$CABA BULLISH

0 · Reply

KNCourt24 Feb. 3 at 8:12 PM

$CABA drop that major pr and send it to $20+

0 · Reply

Achandler787 Feb. 3 at 8:02 PM

$CABA maybe some news coming…

1 · Reply

Cabaletta Bio: Do You Buy With The Insiders?

Jan 12, 2026, 8:00 AM EST - 22 days ago

Cabaletta Bio Announces 2026 Strategic Priorities

Jan 12, 2026, 7:30 AM EST - 22 days ago

IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares' Automated Platforms

Dec 3, 2025, 5:23 PM EST - 2 months ago

Cabaletta Bio, Inc. (CABA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nov 10, 2025, 7:30 AM EST - 3 months ago

Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 4, 2025, 8:00 AM EST - 3 months ago

Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December

Oct 27, 2025, 7:00 AM EDT - 3 months ago

Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025

Oct 14, 2025, 8:00 AM EDT - 4 months ago

Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant

Oct 9, 2025, 12:00 PM EDT - 4 months ago

Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress

Oct 7, 2025, 6:20 AM EDT - 4 months ago

Cabaletta Bio: Still Optimistic, With News Being Guided To Be Shared Soon

Aug 27, 2025, 8:00 AM EDT - 5 months ago

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

Aug 7, 2025, 7:30 AM EDT - 6 months ago

Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 30, 2025, 11:07 AM EDT - 6 months ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

CAPR SRPT NGNE NTLA QURE RCKT

Jun 11, 2025, 9:54 AM EDT - 8 months ago

Cabaletta Bio Announces Pricing of Public Offering of Securities

Jun 11, 2025, 9:49 AM EDT - 8 months ago

Cabaletta Bio: Sector Headwinds And Funding Issues

Jun 11, 2025, 6:15 AM EDT - 8 months ago

Cabaletta Bio Announces Proposed Public Offering of Securities

Jun 11, 2025, 6:00 AM EDT - 8 months ago

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress

May 29, 2025, 8:00 AM EDT - 8 months ago

Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

May 15, 2025, 7:00 AM EDT - 9 months ago

Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts

Mar 31, 2025, 7:00 AM EDT - 11 months ago

Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 19, 2025, 7:00 AM EDT - 11 months ago

Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform

Feb 26, 2025, 8:00 AM EST - 1 year ago

Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 18, 2025, 10:21 AM EST - 1 year ago

UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Feb 18, 2025, 7:00 AM EST - 1 year ago

Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Feb 11, 2025, 8:00 AM EST - 1 year ago

Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February

Jan 29, 2025, 8:00 AM EST - 1 year ago

Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference

Jan 6, 2025, 2:28 PM EST - 1 year ago

Cabaletta Bio: Finding Optimism In Dire Straits

Oct 22, 2024, 11:41 AM EDT - 1 year ago

Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash

Sep 25, 2024, 4:30 PM EDT - 1 year ago

Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 2, 2024, 8:00 AM EDT - 1 year ago

Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum

Jun 28, 2024, 1:42 PM EDT - 1 year ago

Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment

Jun 14, 2024, 2:00 AM EDT - 1 year ago

Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

May 15, 2024, 7:00 AM EDT - 1 year ago

Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update

May 13, 2024, 8:00 AM EDT - 1 year ago

Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Mar 21, 2024, 7:00 AM EDT - 2 years ago

Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 27, 2024, 8:00 AM EST - 2 years ago

Cabaletta Bio to Participate in Upcoming Investor Conferences in March

Feb 1, 2024, 4:30 PM EST - 2 years ago

Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis

Jan 31, 2024, 8:00 AM EST - 2 years ago

Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 31, 2024, 2:53 AM EST - 2 years ago

Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward

Jan 2, 2024, 8:00 AM EST - 2 years ago

Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 11, 2023, 5:58 AM EST - 2 years ago

Cabaletta Bio: Expanding The Success Of CAR-T Beyond Oncology

Dec 10, 2023, 2:44 AM EST - 2 years ago

Buy Cabaletta Bio's Promising SLE Treatment

Nov 28, 2023, 4:30 PM EST - 2 years ago

Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Nov 28, 2023, 3:55 PM EST - 2 years ago

Cabaletta Bio's and Gracell's stock falls sharply as FDA investigates risks of CAR-T therapy

Nov 9, 2023, 7:00 AM EST - 2 years ago

Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 6, 2023, 8:15 AM EST - 2 years ago

Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta's CD19-CAR T Cell Therapy on Cellares' Cell Shuttle Platform

Oct 30, 2023, 8:00 AM EDT - 2 years ago

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November

Sep 19, 2023, 4:56 AM EDT - 2 years ago

Cabaletta Bio: How Long Can Unique Cell Therapy Developer's Sensational Bull Run Continue?

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September

Moonman321 Feb. 4 at 1:34 AM

0 · Reply

Bronco6970 Feb. 3 at 9:42 PM

1 · Reply

nutkicker Feb. 3 at 9:04 PM

$CABA my God you idiots my entire portfolio surged at the end of the day. It's not just CABA. There isn't any magic genie event, something scooped up the entire market dip

1 · Reply

Moonman321 Feb. 3 at 8:33 PM

$CABA you’re obsessed with me 😆

0 · Reply

Moonman321 Feb. 3 at 8:30 PM

$CABA $FVRR $NVDA $PLUG $SKIN Risk on just like that in small caps 💥 This will be a beautiful year for those in small caps

0 · Reply

gata2016 Feb. 3 at 8:25 PM

$CABA Always good to be green on a red day.

0 · Reply

gata2016 Feb. 3 at 8:20 PM

$CABA Back up we go

0 · Reply

Bronco6970 Feb. 3 at 8:19 PM

$CABA BULLISH

0 · Reply

KNCourt24 Feb. 3 at 8:12 PM

$CABA drop that major pr and send it to $20+

0 · Reply

Achandler787 Feb. 3 at 8:02 PM

$CABA maybe some news coming…

1 · Reply

Achandler787 Feb. 3 at 2:23 PM

$CABA all the insiders bought at Market this month: means more than any other release in my opinion. The market is super hard on Biotech right now: Price should be higher!

0 · Reply

robbied61 Feb. 3 at 12:51 PM

$CABA i also hope they partner this drog and dont dilute the stock in the 2 dollar range they burn alit of cash and some very generous salaries they have 5 quarters of cash left according to my math

1 · Reply

robbied61 Feb. 3 at 11:56 AM

$CABA the data on lupus is all that mattersas the data moves forward and shows integrity the price will follow when do they release data update that is theonly thing that matters great data great stock price 👍

0 · Reply

Cap07 Feb. 3 at 9:25 AM

$CABA "Eli Lilly Announces New $3.5 Billion Manufacturing Facility in Pennsylvania" https://www.pharmexec.com/view/eli-lilly-3-billion-manufacturing-facility-pennsylvania Maybe an indirectly good news for Caba, this place could be Biotech hub. Attract researchers, engineers ... What do you think ?

0 · Reply

elmono Feb. 2 at 8:54 PM

$CABA fuck caba

1 · Reply

Majlo Feb. 2 at 5:15 PM

$CABA falsy bottom! 😂

0 · Reply

gata2016 Feb. 2 at 4:40 PM

$CABA I bought more. I will add another seed next week.

0 · Reply

Bronco6970 Feb. 2 at 3:35 PM

$CABA keep in mind: Multiple Cabaletta Bio executives and board members purchased shares in open-market transactions around Jan. 21, 2026, according to recent SEC Form 4 filings💪🚀

0 · Reply

MyDynastyLife Feb. 2 at 2:54 PM

$CABA How you liking that 2.50 now? It was “inevitable”.

1 · Reply

KNCourt24 Feb. 2 at 1:52 PM

$CABA $CHR patience gonna pay⏳💰

0 · Reply

Bronco6970 Feb. 2 at 1:35 PM

$CABA $20++++++++

1 · Reply

KNCourt24 Feb. 2 at 12:50 PM

$CABA $20+

0 · Reply

Market Cap	247.40M
Revenue (ttm)	0.00
Net Income (ttm)	-115.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,915,300
Avg Vol	2,925,962
Day's Range	N/A - N/A
Shares Out	96.27M
Stochastic %K	18%
Beta	3.25
Analysts	Strong Sell
Price Target	$13.12